Measuring surgeon performance of sentinel lymph node biopsy in breast cancer treatment by cumulative sum analysis

Am J Surg. 2007 May;193(5):556-9; discussion 560. doi: 10.1016/j.amjsurg.2007.01.012.

Abstract

Background: This study was performed to determine if surgeons' performance of sentinel lymph node biopsy (SLNB) for breast cancer varied with time and to devise a method to continuously evaluate that performance.

Methods: We retrospectively examined the SLNB experience of 13 community surgeons performing 765 SLNBs and 579 concomitant axillary dissections. False-negative rates (FNRs) were assessed for individuals and cohorts defined by caseload. Performance with time was assessed using cumulative sum (CUSUM) analysis.

Results: Overall, the SLN identification rate was 94.3%, and FNR was 5.3%. Each surgeon demonstrated variation in identification rate and/or FNR with time. CUSUM analysis provided an effective means to demonstrate when surgeon variation breached performance standards.

Conclusions: Surgeon performance of SLNB varied with time, independent of case load. CUSUM may prove to be a useful statistical tool to evaluate performance before adopting stand-alone SLNB.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Biopsy
  • Breast Neoplasms / pathology*
  • Clinical Competence*
  • Employee Performance Appraisal / methods*
  • General Surgery / standards*
  • Humans
  • Middle Aged
  • Retrospective Studies
  • Sentinel Lymph Node Biopsy / standards*
  • Time Factors